biln 2061 profile

BILN 2061: a macrocyclic NS3 protease inhibitor and antiviral agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9853710
CHEMBL ID	297884
SCHEMBL ID	2524642
MeSH ID	M0457324

Synonym
HY-10242
(cyclopentoxycarbonylamino)-[[2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy]-dioxo-[?]carboxylic acid
biln-2061
biln 2061
ciluprevir
biln2061
cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-carboxylic acid, 6-[[(cyclopentyloxy)carbonyl]amino]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, (2
300832-84-2
(2r,6s,13as,14ar,16as,z)-6-(cyclopentyloxycarbonylamino)-2-(2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yloxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxyl
(1s,4r,6s,14s,18r)-14-cyclopentyloxycarbonylamino-18-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-yloxy]-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
(1s,4r,6s,14s,18r)-14-cyclopentyloxycarbonylamino-18-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-yloxy]-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.4,6]nonadec-7-ene-4-carboxylic acid
bdbm50142916
(z)-(1s,4r,6s,14s,18r)-14-cyclopentyloxycarbonylamino-18-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-yloxy]-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
biln 2061 zw
CHEMBL297884 ,
biln-2061-zw
ciluprevir [usan:inn]
unii-75c8du40t0
75c8du40t0 ,
cyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5h)-carboxylic acid, 6-(((cyclopentyloxy)carbonyl)amino)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-((7-methoxy-2-(2-((1-methylethyl)amino)-4-thiazolyl)-4-quinolinyl)oxy)-5,16-dioxo-, (2
(2r,6s,12z,13as,14ar,16as)-6-(((cyclopentyloxy)carbonyl)amino)-2-((7-methoxy-2-(2-((1-methylethyl)amino)thiazol-4-yl)quinolin-4-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a
CS-0339
ciluprevir [usan]
ciluprevir [inn]
(2r,6s,12z,13as,14ar,16as)-6-[[(cyclopentyloxy)carbonyl]amino]-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]thiazol-4-yl]quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a
DB05868
F2145-0237
SCHEMBL2524642
AKOS024627485
ciluprevir;biln 2061zw
(1s,4r,6s,7z,14s,18r)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
Q5120036
(2r,6s,13as,14ar,16as,z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5h)-car
DTXSID50870316

Excerpt	Reference	Relevance
"BILN 2061 is a macrocyclic tripeptide inhibitor of hepatitis C virus NS3-4A protease that has shown efficacy in the clinic for treating patients infected with HCV. "	( Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. He, W; Huang, PP; Kati, WM; Kempf, DJ; Klein, LL; Konstantinidis, AK; Kurtz, KA; Randolph, JT; Zhang, X, 2008)	1.79
"BILN 2061 is a potent, reversible inhibitor of hepatitis C virus NS3/NS4A serine protease. "	( A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Huang, Q; Knight, BL; Pack, FD; Seidler, RW; Stern, JO; Stoltz, JH, 2011)	2.02
"BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. "	( Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. He, W; Huang, PP; Klein, LL; Lu, L; Mo, H; Molla, A; Pilot-Matias, TJ; Pithawalla, R; Randolph, JT; Stewart, KD, 2004)	1.77
"BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro."	( Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Benhamou, Y; Calleja, JL; Chaves, RL; Crönlein, J; Erhardt, A; Forns, X; Hinrichsen, H; Nehmiz, G; Reiser, M; Sentjens, RE; Steinmann, GG; Wedemeyer, H; Yong, CL, 2004)	1.33
"BILN 2061 is a well-tolerated and very active compound that reduced serum viral RNA concentrations after 2 days of treatment in patients infected with genotype 1 HCV independent of the degree of fibrosis. "	( Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Benhamou, Y; Calleja, JL; Chaves, RL; Crönlein, J; Erhardt, A; Forns, X; Hinrichsen, H; Nehmiz, G; Reiser, M; Sentjens, RE; Steinmann, GG; Wedemeyer, H; Yong, CL, 2004)	2.05

Excerpt	Reference	Relevance
"6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R."	( Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G, 2009)	0.35

Excerpt	Reference	Relevance
" Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified."	( Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. Bailey, MD; Bolger, G; Brochu, C; Faucher, AM; Ferland, JM; Garneau, M; Ghiro, E; Gorys, V; Grand-Maître, C; Halmos, T; Lamarre, D; Lapeyre-Paquette, N; Liard, F; Llinàs-Brunet, M; Poirier, M; Rhéaume, M; Tsantrizos, YS, 2004)	0.53
" Macrocyclic beta-strand scaffolds were designed that allowed the discovery of potent, highly selective, and orally bioavailable compounds."	( The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Tsantrizos, YS, 2004)	0.56
" In rats and dogs this compound demonstrated an oral plasma half-life of greater than 7 h, and its bioavailability was >60%."	( Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Beno, DW; Bosse, TD; Chen, CM; He, Y; Hernandez, LE; Kati, WM; Kempf, DJ; Kohlbrenner, WE; Lanford, RE; Larson, DP; Lim, HB; Long, MA; Lu, L; Middleton, T; Molla, A; Pilot-Matias, TJ; Tripathi, RL; Wagner, R, 2007)	0.34
"7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development."	( Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Delouvroy, F; Hu, L; Kock, Hd; Lenz, O; Lin, TI; McGowan, D; Nilsson, M; Raboisson, P; Rosenquist, S; Samuelsson, B; Simmen, K; Surleraux, D; Tahri, A; Vendeville, S; Vreken, WV; Wigerinck, P, 2008)	0.35
"5 h, oral bioavailability of 77%, and a peak liver concentration of 21."	( Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines. Beno, DW; Bosse, TD; Darbyshire, JF; Gao, Y; Gates, BD; He, W; Henry, RF; Hernandez, LE; Hutchinson, DK; Jiang, WW; Kati, WM; Kempf, DJ; Klein, LL; Koev, G; Kohlbrenner, W; Krueger, AC; Larson, DP; Liu, J; Liu, Y; Long, MA; Maring, CJ; Masse, SV; Middleton, T; Molla, A; Montgomery, DA; Pratt, JK; Stuart, P; Wagner, R, 2009)	0.35

Excerpt	Relevance	Reference
" The design included oral dosing of 30 mg per kg of body weight twice a day for 14 days, followed by a 14-day posttreatment observation."	( Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Beno, DW; Bosse, TD; Chen, CM; He, Y; Hernandez, LE; Kati, WM; Kempf, DJ; Kohlbrenner, WE; Lanford, RE; Larson, DP; Lim, HB; Long, MA; Lu, L; Middleton, T; Molla, A; Pilot-Matias, TJ; Tripathi, RL; Wagner, R, 2007)	0.34
" Echocardiographic traces obtained after twenty-eight consecutive days of dosing revealed two animals with diminished left ventricular cardiac ejection fraction."	( A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Huang, Q; Knight, BL; Pack, FD; Seidler, RW; Stern, JO; Stoltz, JH, 2011)	0.58

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Genome polyprotein		IC50 (µMol)	0.0008	0.0000	0.0289	0.1870	AID1161415
Genome polyprotein		Ki	0.0003	0.0000	0.0067	0.0300	AID1173945
Genome polyprotein		IC50 (µMol)	3.0000	0.7000	1.9567	3.8000	AID241120
Genome polyprotein		Ki	0.0068	0.0000	0.0028	0.0200	AID1383023; AID1383024; AID292989
NS3 protease		Ki	0.2000	0.0039	0.0829	0.2000	AID1073073
Non-structural protein 4A		IC50 (µMol)	0.0008	0.0000	0.0289	0.1870	AID1161415
Non-structural protein 4A		Ki	0.0003	0.0000	0.0067	0.0300	AID1173945
Cytochrome P450 1A2	Homo sapiens (human)	Ki	0.1200	0.0056	1.1534	9.0000	AID1073074
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.0240	0.0001	1.4162	9.9000	AID1073072
Cytochrome P450 2D6	Homo sapiens (human)	Ki	0.1200	0.0001	1.1986	8.0000	AID1073074
Cytochrome P450 2C9	Homo sapiens (human)	Ki	0.2000	0.0003	1.6842	10.0000	AID1073073
Cytochrome P450 2C19	Homo sapiens (human)	Ki	0.0240	0.0001	0.8300	10.0000	AID1073072
NS3 protease	Hepatitis C virus subtype 1b	Ki	0.0720	0.0090	1.2670	6.1000	AID1073072; AID1073074
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (254)

Assay ID	Title	Year	Journal	Article
AID577352	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577608	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80H mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID322947	Antiviral activity against Hepatitis C virus infected human hepatoma cells by replicon assay	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID577377	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577349	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508189	Inhibition of Hepatitis C virus genotype 1b NS3/4A protease activity	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577633	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V170T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1242954	Cytotoxicity against human GS4.1 cells assessed as induction of cell death	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
AID577622	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID664167	Antiviral activity against Hepatitis C virus subtype 1b harboring protease R155K mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521269	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M/R155K double mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID555950	Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1071917	Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID577357	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R109K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577620	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577625	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168N mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423483	Drug resistance, ratio of EC50 for HCV 1a H77 with NS5B polymerase G554D mutation to EC50 for wild type HCV 1a H77 infected in chimpanzee measured on day 5	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID423477	Drug resistance, ratio of EC50 for HCV 1b strain N with NS5B polymerase C316Y mutation to EC50 for wild type HCV 1b strain N infected in chimpanzee measured on day 28	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID1071913	Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID344556	Inhibition of full length HCV NS3/4A protease	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
AID11485	Vss was determined	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID573110	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1161416	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human Huh7 cells assessed as inhibition of NS4A expression by ELISA	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
AID521275	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 T54A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577363	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577617	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577607	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508185	Antiviral activity against Hepatitis C virus genotype 1b infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 50% normal human serum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID423480	Antiviral activity against HCV 1a H77 with NS5B polymerase G554D mutation infected in chimpanzee measured on day 16	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577390	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q41R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577378	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V170T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID394182	Antiviral activity against HCV genotype 1 infected in human assessed as reduction in viral titer after 48 hrs	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
AID1071911	Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID577388	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36 M mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID491861	Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID577614	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155M mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577364	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1071915	Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID711483	Protein binding in human plasma	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID577342	Antiviral activity against Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1161415	Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
AID612410	Inhibition of HCV NS3 protease	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID1383026	Cytotoxicity against human HuH7 cell	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Pan-NS3 protease inhibitors of hepatitis C virus based on an R
AID1072931	Inhibition of Hepatitis C virus genotype 1a full length NS3/2K-NS4A protease using Ac-DED(Edans)EEAbupsi[COO]ASK(Dabcyl)-NH2 as substrate incubated for 10 mins prior to substrate addition by FRET analysis	2014	ACS medicinal chemistry letters, Mar-13, Volume: 5, Issue:3	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.
AID577344	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36M mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423474	Drug resistance, ratio of EC50 for HCV 1b strain N with NS5B polymerase C316Y mutation to EC50 for wild type HCV 1b strain N infected in chimpanzee measured on day 2	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577631	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423482	Drug resistance, ratio of EC50 for HCV 1a H77 with NS5B polymerase G554D mutation to EC50 for wild type HCV 1a H77 infected in chimpanzee measured on day 2	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID1383024	Inhibition of HCV genotype-1a NS3 protease	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Pan-NS3 protease inhibitors of hepatitis C virus based on an R
AID1383025	Antiviral activity against HCV genotype 1b infected in human HuH7 cells	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Pan-NS3 protease inhibitors of hepatitis C virus based on an R
AID328998	Inhibition of HCV NS3-4A protease	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
AID577373	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168Y mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577641	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and D168A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577376	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577371	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423475	Drug resistance, ratio of EC50 for HCV 1b strain N with NS5B polymerase C316Y mutation to EC50 for wild type HCV 1b strain N infected in chimpanzee measured on day 5	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID521259	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V170A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 10 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1071921	Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID654781	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh cells by luciferase reporter gene based replicon assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
AID1073074	Inhibition of full-length HCV NS3 protease A156T mutant	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
AID146238	Inhibition of hepatitis C virus in a cell based HCV replicon assay.	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID711485	Half life in monkey	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID344557	Inhibition of HCV replication in human HuH7-Rep cells containing subgenomic bicistronic clone	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
AID241120	Inhibitory concentration against hepatitis C virus NS3 protease	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Control of hepatitis C: a medicinal chemistry perspective.
AID577384	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID711489	Oral bioavailability in dog	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID577626	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423469	Antiviral activity against wild type HCV 1b strain N infected in chimpanzee	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577605	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 T54A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577628	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168Y mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521267	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577380	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S and Q80R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1073075	Inhibition of full-length wild-type HCV NS3 protease	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
AID423473	Antiviral activity against HCV 1b strain N with NS5B polymerase C316Y mutation infected in chimpanzee measured on day 28	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577369	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID555951	Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID711491	Oral bioavailability in rat	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID444180	Cytotoxicity against human Huh7.5 cells	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	New small molecule inhibitors of hepatitis C virus.
AID555954	Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID521271	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID546789	Antiviral activity against Hepatitis C virus genotype 1b in luciferase encoding genotype 1b replicons after 3 days by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID577640	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80H and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577391	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID711487	Half life in dog	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1071918	Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID577612	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R109K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID641102	Inhibition of Hepatitic C virus NS3/4A protease by FRET assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L.
AID173105	Maximum plasma concentration in rats after oral administration at 20 mg/kg	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID577637	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80K and R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577351	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 T54S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577623	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID664161	Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168V mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID322946	Inhibition of HCV NS3 protease by FRET assay	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID711502	Inhibition of HCV 1b NS3 protease	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID577345	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577375	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521265	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577362	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577353	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80H mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1242952	Inhibition of full length HCV 1b Con1 NS3/4A protease using HiLyte Fluor 610 peptide substrate by biochemical FRET assay	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
AID664162	Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168A mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID598530	Antiviral activity against HCV genotype 1b infected in Huh7 cells assessed as inhibition of viral replication by cell-based replicon assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
AID577387	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36L mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID664163	Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156V mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID423471	Antiviral activity against HCV 1b strain N with NS5B polymerase C316Y mutation infected in chimpanzee measured on day 5	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID423481	Antiviral activity against HCV 1a H77 with NS5B polymerase Y448C mutation infected in chimpanzee measured on day 28	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577354	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577361	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155Q mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577606	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 T54S mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577386	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and D168A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423470	Antiviral activity against HCV 1b strain N with NS5B polymerase C316Y mutation infected in chimpanzee measured on day 2	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID423484	Drug resistance, ratio of EC50 for HCV 1a H77 with NS5B polymerase G554D mutation to EC50 for wild type HCV 1a H77 infected in chimpanzee measured on day 16	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID12746	Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID577635	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S and Q80R mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID146239	Inhibitory concentration against hepatitis C virus NS3 protease	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID523615	Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID577613	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 S138T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577383	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80R and R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521266	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID444179	Antiviral activity against HCV2a J6/JFH1 infected in Huh7-5 cells assessed as inhibition of core protein dimerization by RT PCR	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	New small molecule inhibitors of hepatitis C virus.
AID577367	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID595272	Antiviral activity against Hepatitis C virus infected in human Ava5 cells assessed as decreased NS3 protein level at 20 nM after 72 hrs by Western blotting	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Diosgenin, a plant-derived sapogenin, exhibits antiviral activity in vitro against hepatitis C virus.
AID664159	Antiviral activity against Hepatitis C virus subtype 1b by stable replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521273	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID444181	Antiviral activity against HCV2a J6/JFH1 infected in Huh7-5 cells at early T1 stage assessed as inhibition of core protein dimerization by RT PCR	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	New small molecule inhibitors of hepatitis C virus.
AID577632	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577347	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521255	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 100 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID509556	Inhibition of HCV NS3 protease	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
AID180765	Bioavailability in rat (dose 5 mg/kg i.v.)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID598531	Inhibition of HCV 1a NS3/4A protease	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
AID509557	Antiviral activity against HCV Con1 by cell based-luciferase reporter gene assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
AID577603	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577381	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43S and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID491860	Inhibition of HCV NS3 protease by FRET assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID508188	Inhibition of Hepatitis C virus genotype 2a NS3/4A protease activity	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577358	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 S138T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID555952	Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID664165	Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156S mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID573108	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID394178	Antiviral activity against HCV isolate Con1 in human Huh7 cells assessed as reduction in viral RNA after 7 days by RT-PCR	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
AID577611	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80L mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423478	Antiviral activity against HCV 1a H77 with NS5B polymerase G554D mutation infected in chimpanzee measured on day 2	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577629	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168H mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID649649	Antiviral activity against HCV genotype 1b infected in human Huh cells expressing luc gene by replicon assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.
AID171332	Plasma clearance after intravenous administration at 5 mg/kg in rats	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID423476	Drug resistance, ratio of EC50 for HCV 1b strain N with NS5B polymerase C316Y mutation to EC50 for wild type HCV 1b strain N infected in chimpanzee measured on day 11	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID612408	Antiviral activity against HCV	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID573106	Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID444182	Antiviral activity against HCV2a J6/JFH1 infected in Huh7-5 cells at late T2 stage assessed as inhibition of core protein dimerization by RT PCR	2009	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24	New small molecule inhibitors of hepatitis C virus.
AID577348	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 F43I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID508186	Antiviral activity against Hepatitis C virus genotype 1b infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 10% fetal bovine serum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577382	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80K and R155K mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577616	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155Q mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577389	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V36A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID546790	Antiviral activity against Hepatitis C virus genotype 1a in luciferase encoding genotype 1a replicons after 3 days by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID577634	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 V170A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577610	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID711486	Half life in rat	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID322793	Inhibition of RNA copy numbers in HCV 1b-N replicon cells with NS5B M414T mutant at EC50 after 4 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
AID711501	Inhibition of HCV 1a NS3 protease	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID573105	Cytotoxicity against human HuH6 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID664160	Antiviral activity against Hepatitis C virus subtype 1a by stable replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID577618	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577385	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80H and D168E mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577615	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155I mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521256	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 100 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577355	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1071920	Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521268	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156S mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1645924	Antiviral activity against HCV	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	A review on HCV inhibitors: Significance of non-structural polyproteins.
AID322795	Inhibition of RNA copy numbers in HCV 1b-N replicon cells with NS5B M414T mutant at 100 times EC50 after 4 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
AID577350	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 T54A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577374	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168H mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577639	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID555943	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 5 passages at 1 uM by quantitative RT-PCR relative to wild type virus	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID577356	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q80L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID573107	Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID591091	Cytotoxicity against human Huh7.5 cells	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.
AID521270	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID521263	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 10 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID292989	Inhibition of HCV 1a NS3 protease	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
AID711490	Antiviral activity against HCV1b by cell based replicon assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1072927	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells by subgenomic replicon-based luciferase assay	2014	ACS medicinal chemistry letters, Mar-13, Volume: 5, Issue:3	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.
AID1173954	Antiviral activity against HCV genotype 1a	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
AID508187	Inhibition of Hepatitis C virus genotype 2b NS3/4A protease activity	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577604	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43V mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID328999	Antiviral activity against HCV replicon	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
AID508190	Inhibition of Hepatitis C virus genotype 1a NS3/4A protease activity	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID394177	Antiviral activity against HCV 1a containing chimeric genotype 1a-H77/1b-con1 subgenom in human Huh7 cells assessed as reduction in viral RNA after 7 days by RT-PCR	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
AID322796	Antiviral activity against HCV 1b-N	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
AID423485	Drug resistance, ratio of EC50 for HCV 1a H77 with NS5B polymerase Y448C mutation to EC50 for wild type HCV 1a H77 infected in chimpanzee measured on day 28	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID577638	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80R and R155K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1383023	Inhibition of HCV genotype-3a full length NS3 protease preincubated for 10 mins followed by Ac-DED(Edans)EEAbuj-[COO]ASK(Dabcyl)-NH2 addition in presence of co-factor 2K-NS4A by fluorescence assay	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Pan-NS3 protease inhibitors of hepatitis C virus based on an R
AID521274	Antiviral activity against wild-type Hepatitis C virus genotype 1b N infected in human Huh7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID521272	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155Q mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID654780	Inhibition of Hepatitis C virus genotype 1b NS3/4A protease	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
AID577609	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 Q80K mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID664158	Inhibition of HCV 1a protease 1a domain	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID577366	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156G mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577343	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V36L mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1173945	Inhibition of HCV genotype 1a NS3/4A protease using Ac-DED(Edans)EEAbu-psi[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
AID591089	Antiviral activity against Hepatitis C virus JFH-1 J6 infected in human HuH7.5 cells assessed as inhibition of virus propagation measured after 72 hrs	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.
AID1071914	Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID573111	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID664166	Antiviral activity against wild type Hepatitis C virus subtype 1b by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1071910	Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521261	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 10 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577368	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156V mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1071916	Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID711488	Oral bioavailability in monkey	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID10630	Half-life period in rats after intravenous administration at 5 mg/kg	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
AID555953	Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID711492	Antiviral activity against HCV1a by cell based replicon assay	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID577379	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 V170A mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID573112	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID555941	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 5 passages at 1 uM by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID577636	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 F43S and D168E mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1073072	Inhibition of full-length HCV NS3 protease R155K mutant	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
AID1071919	Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID423479	Antiviral activity against HCV 1a H77 with NS5B polymerase G554D mutation infected in chimpanzee measured on day 5	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID521258	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 100 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID292988	Inhibition of HCV 1b NS3 protease	2007	Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3	Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
AID577359	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155M mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577372	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168T mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID521264	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V170A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID521276	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V170A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 100 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID508184	Antiviral activity against Hepatitis C virus genotype 2a infected in mouse HB1 cell by cell-based HCV replicon assay in presence of 10% fetal bovine serum	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577621	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 A156G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID344558	Metabolic stability in human liver microsomess after 15 mins at 5 uM	2008	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18	Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
AID577365	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 A156S mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID664164	Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156T mutant by transient replicon assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1242953	Antiviral activity against HCV Con1 infected in human GS4.1 cells containing HCV Con1 subgenomic replicon assessed as reduction in NS5A protein expression by ELISA method	2015	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18	Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
AID577627	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168T mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID591090	Antiviral activity against Hepatitis C virus JFH-1 J6 infected in human HuH7.5 cells assessed as inhibition of virus propagation measured after 72 hrs of transfer to fresh media	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.
AID555955	Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID322794	Inhibition of RNA copy numbers in HCV 1b-N replicon cells with NS5B M414T mutant at 10 times EC50 after 4 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
AID577630	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168A mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577619	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 R155G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID649647	Inhibition of HCV1b NS3/4A protease	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.
AID521257	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155Q mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 100 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1071912	Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID523614	Antiviral activity against cyclosporine A/NIM811-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by qRT-PCR analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID577360	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 R155I mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID573109	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID521262	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155Q mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 10 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID577370	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 D168N mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID423472	Antiviral activity against HCV 1b strain N with NS5B polymerase C316Y mutation infected in chimpanzee measured on day 11	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
AID508183	Cytotoxicity against mouse HB-1 cells	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
AID577346	Antiviral activity against Hepatitis C virus subtype 1b expressing NS3 Q41R mutant infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID577624	Ratio of EC50 for Hepatitis C virus subtype 1b expressing NS3 D168G mutant to EC50 for Hepatitis C virus subtype 1b expressing WT NS3 infected in HuH7 cells after 48 hrs by by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
AID1073073	Inhibition of full-length HCV NS3 protease D168V mutant	2014	Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
AID521260	Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at 10 nM	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1799853	Competitive Inhibition Assay from Article 10.1021/bi9016928: \\Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.\\	2009	Biochemistry, Dec-08, Volume: 48, Issue:48	Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	47 (56.63)	29.6817
2010's	36 (43.37)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (8.33%)	5.53%
Reviews	3 (3.57%)	6.00%
Case Studies	1 (1.19%)	4.05%
Observational	0 (0.00%)	0.25%
Other	73 (86.90%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbamates [no description available]	9.07	47	6	amino-acid anion
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	3.53	2	0
patulin Patulin: 4-Hydroxy-4H-furo(3,2-c)pyran-2(6H)-one. A mycotoxin produced by several species of Aspergillus and Penicillium. It is found in unfermented apple and grape juice and field crops. It has antibiotic properties and has been shown to be carcinogenic and mutagenic and causes chromosome damage in biological systems.. patulin : A furopyran and lactone that is (2H-pyran-3(6H)-ylidene)acetic acid which is substituted by hydroxy groups at positions 2 and 4 and in which the hydroxy group at position 4 has condensed with the carboxy group to give the corresponding bicyclic lactone. A mycotoxin produced by several species of Aspergillus and Penicillium, it has antibiotic properties but has been shown to be carcinogenic and mutagenic.	3.12	1	0	furopyran; gamma-lactone; lactol	antimicrobial agent; Aspergillus metabolite; carcinogenic agent; mutagen; mycotoxin; Penicillium metabolite
trifluoperazine [no description available]	3.12	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.42	2	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.03	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	4.8	2	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
michler's ketone [no description available]	3.12	1	0	benzophenones
cyclohexanol Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.	4.41	1	1	cyclohexanols; secondary alcohol	solvent
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	4.41	1	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.07	1	0	catechin	antioxidant; plant metabolite
thiazoles [no description available]	9.07	47	6	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiophene-2-carboxylate thiophene-2-carboxylic acid : A thiophenecarboxylic acid in which the carboxy group is located at position 2.	2.04	1	0	thiophenecarboxylic acid
neutral red base neutral red base : A member of the class of phenazines carrying methyl, amino and dimethylamino substituents at positions 2, 3 and 7 respectively. The free base of neutral red, which acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.	3.12	1	0	aromatic amine; phenazines; primary amino compound; tertiary amino compound	acid-base indicator; dye; two-colour indicator
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.03	1	0	metal allergen; nickel group element atom; platinum group metal atom
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.12	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
ribavirin Rebetron: Rebetron is tradename	2.05	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	3.12	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	3.31	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
gallocatechol gallocatechol: structure give in first source; RN given for (trans-(+-))-omer; inhibits DNA-dependent DNA & RNA polymerases. (+)-gallocatechin : A gallocatechin that has (2R,3S)-configuration. It is found in green tea and bananas.. gallocatechin : A catechin that is a flavan substituted by hydroxy groups at positions 3, 3', 4', 5, 5' and 7 (the trans isomer). It is isolated from Acacia mearnsii.	2.07	1	0	gallocatechin	antioxidant; metabolite; radical scavenger
corilagin corilagin: isolated from Geranii herba. corilagin : An ellagitannin with a hexahydroxydiphenoyl group bridging over the 3-O and 6-O of the glucose core.	2.07	1	0	ellagitannin; gallate ester	antihypertensive agent; antioxidant; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; non-steroidal anti-inflammatory drug
diosgenin [no description available]	2.06	1	0	3beta-sterol; hexacyclic triterpenoid; sapogenin; spiroketal	antineoplastic agent; antiviral agent; apoptosis inducer; metabolite
ribavirin 5'-triphosphate ribavirin 5'-triphosphate: structure given in first source. ribavirin 5'-triphosphate : A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin.	3.12	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide; ribose triphosphate	antiviral agent; drug metabolite; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; eukaryotic initiation factor 4F inhibitor; human blood serum metabolite
ribavirin 5'-diphosphate ribavirin 5'-diphosphate : A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a diphosphate group. It is the metabolite of the antiviral agent ribavirin.	3.12	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide; ribose diphosphate	antiviral agent; drug metabolite
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	3.44	7	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	3.16	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
Chebulagic acid [no description available]	2.07	1	0	tannin
4'-azidocytidine 4'-azidocytidine: antiviral; structure in first source	2.45	2	0	N-glycosyl compound
amd 8664 [no description available]	3.16	1	0
4-phenyl-4-oxo-2-hydroxybuten-2-oic acid 2,4-dioxo-4-phenylbutanoic acid: structure in first source	3.12	1	0
2'-c-methyladenosine 2'-C-methyladenosine: antiviral	2.45	2	0
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.45	2	0
phenylthiourea Phenylthiourea: Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless.. N-phenylthiourea : A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a phenyl group. Depending on their genetic makeup, humans find it either very bitter-tasting or tasteless. This unusual property resulted in N-phenylthiourea being used in paternity testing prior to the advent of DNA testing.	2.46	2	0	thioureas	EC 1.14.18.1 (tyrosinase) inhibitor
Geraniin [no description available]	2.07	1	0	tannin
telaprevir [no description available]	8.06	26	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	2.07	1	0	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.74	3	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
cyclotheonamide a cyclotheonamide A: a cyclic peptide isolated from the marine sponge Theonella; structure given in first source	3.16	1	0
koaburaside koaburaside: an anti-histamine compound from Aeschynanthus bracteatus; structure in first source	2.07	1	0
(melle-4)cyclosporin (melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A	2.05	1	0
sm360320 SM360320: Proc Natl Acad Sci U S A 2006 Feb 7;103(6):1828-33	3.31	1	0
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	4.87	10	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
furosin furosin: an ellagitannin from extract of leaves & stems of Phyllanthus sellowianus; structure given in first source	2.07	1	0
danoprevir [no description available]	5.18	8	0
alisporivir alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source	2.45	2	0	homodetic cyclic peptide	anticoronaviral agent
ulimorelin ulimorelin: ghrelin agonist; an 18-membered macrocycle containing 3 amide bonds and a secondary amine as well as 4 stereogenic centers; belongs to macrocyclic peptidomimetics	3.16	1	0	oligopeptide
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	2.45	2	0
narlaprevir narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.	3.31	1	0	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor
sch6 SCH6: hepatitis C virus NS3/4A protease inhibitor; structure in first source	2.44	2	0
bms-650032 asunaprevir: an NS3 protease inhibitor against hepatitis C virus	3.31	1	0	oligopeptide
oligonucleotides [no description available]	4.41	1	1
mk-7009 vaniprevir: inhibits hepatitis C virus NS3/4a protease. vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan.	4.28	5	0	azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide	antiviral drug; hepatitis C protease inhibitor
lomibuvir lomibuvir: an antiviral agent with polymerase NS5 inhibitory activity	4.41	1	1	thiophenecarboxylic acid
gs-9256 GS-9256: has antiviral activity; structure in first source	2.07	1	0
simeprevir [no description available]	4.08	4	0	azamacrocycle; lactam
robotnikinin robotnikinin: binds sonic hedgehog protein to block its signaling pathway; structure in first source	3.16	1	0
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	4.8	2	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
gs-9451 [no description available]	3.46	1	1
bi 201335 faldaprevir: inhibits hepatitis C virus NS3 protease	4.11	4	0
tmc647055 [no description available]	3.31	1	0
grazoprevir grazoprevir: has antiviral activity; component of Zepatier. grazoprevir : An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.	3.31	1	0	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent
miravirsen miravirsen: has antiviral activity; a 15-nucleotide locked nucleic acid-modified antisense oligonucleotide that inhibits miR-122	4.41	1	1
danoprevir [no description available]	2.1	1	0

Condition	Relationship Strength	Studies	Trials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	7.81	22	2
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	7.81	22	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.72	3	0
Chronic Hepatitis C [description not available]	12.23	8	5
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	7.23	8	5
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.03	1	0
Cardiac Diseases [description not available]	2.03	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.03	1	0

biln 2061

Description

Cross-References

Synonyms (34)

Research Excerpts

Overview

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (10)

Inhibition Measurements

Biological Processes (42)

Molecular Functions (34)

Ceullar Components (6)

Bioassays (254)

Research

Studies (83)

Market Indicators

Research Demand Index: 17.48

Study Types

biln 2061

Description

Cross-References

Synonyms (34)

Research Excerpts

Overview

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (10)

Inhibition Measurements

Biological Processes (42)

Molecular Functions (34)

Ceullar Components (6)

Bioassays (254)

Research

Studies (83)

Market Indicators

Research Demand Index: 17.48

Study Types

Related Drugs (63)

Related Conditions (8)